# Menlo Ventures’ 2026 State of AI in Healthcare Report: Healthcare AI Spending Hits $3.7B, Up 2.5x as Growth Shifts From Paperwork to Drug Discovery and Patient Care

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/menlo-ventures-2026-state-of-ai-in-healthcare-report-healthcare-ai-spending-hits-3-7b-up-2/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Life sciences AI spend surged 23x this year, clinical copilots grew 5.5x, and incumbents took 68% of new scribe dollars as healthcare AI moved beyond administrative work and closer to the patient*

Healthcare Leads Vertical AI

<figure><img src="https://ml.globenewswire.com/Resource/Download/a1719d7f-0f5b-4072-851c-29d86f62b877" alt="Healthcare is the largest vertical AI market. Spend grew 2.5x to $3.7B in 2026, more than double the next-largest vertical, legal ($1.8B, +2.8x YoY)." loading="lazy"><figcaption>Healthcare is the largest vertical AI market. Spend grew 2.5x to $3.7B in 2026, more than double the next-largest vertical, legal ($1.8B, +2.8x YoY).</figcaption></figure>

Life Sciences: From Pilots to Scaled Production in a Year

<figure><img src="https://ml.globenewswire.com/Resource/Download/edaff336-f917-4c4f-a02f-abcdbcafe90c" alt="In 2026, pharma and biotech moved from pilots to production. 43% of life sciences companies now run AI at scale, up from 12% in 2025, led by pharma at 51% (from 15%) and biotech at 35% (from 9%)." loading="lazy"><figcaption>In 2026, pharma and biotech moved from pilots to production. 43% of life sciences companies now run AI at scale, up from 12% in 2025, led by pharma at 51% (from 15%) and biotech at 35% (from 9%).</figcaption></figure>

Who Captures Healthcare AI Spend?

<figure><img src="https://ml.globenewswire.com/Resource/Download/5c13888f-a6f8-432d-aaab-947d7b1ae7e9" alt="Healthcare is buying specialized AI. Industry-specific vendors capture 50% of all healthcare AI spending, more than double their 24% share across all enterprises. Providers lead at (53%), followed by life sciences (43%), while payers (30%) look more like the broader enterprise market." loading="lazy"><figcaption>Healthcare is buying specialized AI. Industry-specific vendors capture 50% of all healthcare AI spending, more than double their 24% share across all enterprises. Providers lead at (53%), followed by life sciences (43%), while payers (30%) look more like the broader enterprise market.</figcaption></figure>

MENLO PARK, Calif., Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- Menlo Ventures, a leading venture capital firm investing at the forefront of artificial intelligence, today released its <a href="https://menlovc.com/perspective/2026-the-state-of-ai-in-healthcare/" rel="nofollow">2026: The State of AI in Healthcare report</a>, finding that healthcare AI spending reached **$3.7 billion**, up **2.5x** in a year. While AI’s early successes in healthcare focused on administrative tasks like documentation and billing, the report finds the fastest growth now comes from drug discovery, clinical decision-making, and patient care.

“AI is transforming healthcare," said Greg Yap, Venture Partner at Menlo Ventures. “Earlier software could never automate healthcare’s hardest work, but frontier models and AI agents are now expanding from the back office into the bench and the bedside. We’re still in the early stages, but our research shows that the healthcare sector is leading the way in AI investment, driven by AI’s potential to improve health outcomes and lower costs for everyone.”

Nowhere is that potential more evident than in life sciences, where AI spending surged **23x** this year as pharmaceutical companies look to accelerate drug discovery and development.

“We expect AI to usher in a new era of drug discovery, bringing better medicines to patients faster,” said Johnny Hu, Ph.D., Principal at Menlo Ventures. “Today, developing a new drug takes more than a decade and billions of dollars with a 90% failure rate in the clinic. AI offers a chance to change those odds and develop medicines for previously intractable diseases. Ultimately, success won’t be measured by how much pharma invests in AI, but by the new medicines that reach patients and the lives they improve.”

“In just one year, the healthcare AI market has changed dramatically,” said JP Sanday, Partner at Menlo Ventures. “Startups pioneered AI scribing, but incumbents moved quickly, with Microsoft and Epic now capturing roughly two of every three new scribe dollars. Meanwhile, growth is shifting to entirely new opportunities: life sciences AI spending surged 23x, clinical copilots grew 5.5x, and patient engagement grew 4.5x. For AI-native startups, the opportunity is no longer just making existing workflows more efficient. It’s building products that fundamentally change how healthcare is delivered, making care more proactive, personalized, and accessible, rather than something patients have to navigate one appointment at a time.”

**Key Findings**

-   **Healthcare is AI’s largest vertical market.** Spending grew **2.5x** to **$3.7 billion**, more than legal and finance combined and more than double the next-largest vertical, legal (**$1.8 billion**). **50%** of it goes to healthcare-specific applications, about twice the enterprise average, and providers account for **77%** (**$2.9 billion**).
-   **AI for drug discovery is breaking out.** Life sciences AI spending surged **23x**, from **$30 million** to **$700 million**, the fastest growth of any healthcare AI segment. **51%** of pharma companies now run AI at scale, up from **15%** a year ago, and **84%** of R&D leaders expect AI to reduce development timelines by at least a year over the next three to five years. Proof is still ahead: **93%** expect first approval of an AI-discovered drug within five years, but only **28%** within two.
-   **The provider market is evolving rapidly as incumbents strike back.** Every major EHR now offers its own scribe, and this year incumbents captured 68% of new scribe dollars, growing their share to **46%** of the **$950 million** market, up from **33%** a year ago. AI-native scribes grew **28%** but lost share, but are expanding into new areas like prior authorization.
-   **AI innovation is moving closer to the patient.** Clinical copilots grew **5.5x** to **$550 million** and patient engagement AI grew **4.5x** to **$450 million**, versus **1.6x** for scribes and **1.3x** for coding and billing.
-   **Payers are paying for providers’ AI, not their own.** Payers’ external AI spend was just **$150 million** (**4%** of the market), yet **43%** of payers (**57%** of large payers) say provider AI coding has raised their medical cost trend in 2026, up from **23%** in 2025. Prior authorization is now their top AI priority at **82%**, up from **59%**.  
      
    

**About the 2026 State of AI in Healthcare Report**

Now in its second year, Menlo Ventures’ <a href="https://menlovc.com/perspective/2026-the-state-of-ai-in-healthcare/" rel="nofollow">The State of AI in Healthcare</a> examines how healthcare organizations are buying and deploying AI, where they are spending, and which companies are capturing that spending.

The 2026 report draws on a survey o**f 550 U.S. healthcare and life sciences executives** at the director level and above who have participated in procuring an AI solution for their organization. Respondents include **150 technology decision-makers** at provider organizations, **100 senior executives** at health plans and benefits administrators, and 300 executives at pharmaceutical and biotech companies developing their own therapeutics.

The report explores how AI is transforming drug development, care delivery, and health insurance. It is authored by Menlo Ventures’ healthcare investors Greg Yap, JP Sanday, Croom Beatty, Johnny Hu, Ph.D., Derek Xiao, and Sabrina Lu.

<a href="https://menlovc.com/perspective/2026-the-state-of-ai-in-healthcare/" rel="nofollow">Read the full report, including detailed findings and methodology.</a>

**About Menlo Ventures**  
For 50 years, Menlo Ventures has backed companies that change how the world works, from <a href="https://www.gilead.com/" rel="nofollow">Gilead Sciences</a> to <a href="http://www.uber.com/" rel="nofollow">Uber</a> to <a href="https://www.anthropic.com/" rel="nofollow">Anthropic</a>. Today, Menlo is at the forefront of the AI transformation, investing across the technology stack, from foundation models (<a href="https://www.anthropic.com/" rel="nofollow">Anthropic</a>) and infrastructure (<a href="https://openrouter.ai/" rel="nofollow">OpenRouter</a>, <a href="https://fireworks.ai/" rel="nofollow">Fireworks</a>, <a href="https://modal.com/" rel="nofollow">Modal</a>) to breakthrough applications (<a href="https://lovable.dev/" rel="nofollow">Lovable</a>, <a href="https://higgsfield.ai/" rel="nofollow">Higgsfield</a>, <a href="https://legora.com/" rel="nofollow">Legora</a>, <a href="https://www.openevidence.com/" rel="nofollow">OpenEvidence</a>, and <a href="http://wisprflow.ai/" rel="nofollow">Wispr Flow</a>). Menlo’s investment team brings together experienced investors, former founders, engineers, and technology executives who understand firsthand what it takes to build and scale a company. That experience informs every founder partnership, bringing practical insight and perspective to the challenges of building a business and scaling it into a market leader. Menlo invests from inception through growth across consumer, enterprise, and healthcare. In June 2026, the firm marked its 50th anniversary and announced $3 billion in fresh capital to back the next generation of AI companies.

**Media Contact**

Nectar Communications

menlo@nectarpr.com

Photos accompanying this announcement are available at:

<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/a1719d7f-0f5b-4072-851c-29d86f62b877" rel="nofollow">https://www.globenewswire.com/NewsRoom/AttachmentNg/a1719d7f-0f5b-4072-851c-29d86f62b877</a>

<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/edaff336-f917-4c4f-a02f-abcdbcafe90c" rel="nofollow">https://www.globenewswire.com/NewsRoom/AttachmentNg/edaff336-f917-4c4f-a02f-abcdbcafe90c</a>

<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/5c13888f-a6f8-432d-aaab-947d7b1ae7e9" rel="nofollow">https://www.globenewswire.com/NewsRoom/AttachmentNg/5c13888f-a6f8-432d-aaab-947d7b1ae7e9</a>

  
![](https://ml.globenewswire.com/media/M2M4MmEzOTktN2UxZC00M2E5LTgxNzgtMGYwZmQ4M2IyMGE1LTUwMDA2Mzk1Mi0yMDI2LTExLTE2LWVu/tiny/Menlo-Ventures.png)

## Related

- [Generative AI in Healthcare Market Size to worth US$ 19.72 Billion by 2033, Coherent Market Insights](https://healthcarenews.io/news/generative-ai-in-healthcare-market-size-to-worth-us-19-72-billion-by-2033-coherent-market.md)
- [Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights](https://healthcarenews.io/news/helus-pharma-reports-second-quarter-fiscal-2027-financial-results-and-recent-business-high.md)
- [Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology](https://healthcarenews.io/news/kestra-announces-publication-of-ace-pas-the-largest-prospective-real-world-wearable-defibr.md)
- [Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations](https://healthcarenews.io/news/alamar-biosciences-highlights-nulisa-data-in-46-presentations-at-ctad-2026-including-10-or.md)
